Roche gets EC nod for Phesgo to treat HER2-positive breast cancer
Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase designed to be used as subcutaneous (SC) injection. Phesgo integrates the same monoclonal antibodies as